Glucagon-like Peptide-1 and Coronary Microvascular Dysfunction in Women With Angina Pectoris and no Coronary Stenosis

• Status: Completed
• Trial end date: 2017-04-18
• Target enrollment: 0
• Participant gender: Female

Summary

The aim of the present study is to evaluate the effect of treatment with Liraglutide on the coronary microvasculature and angina symptoms, in overweight patients with microvascular dysfunction and angina pectoris but no coronary artery stenosis.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eva Prescott
• Treatments: Glucagon; Glucagon-Like Peptide 1; Liraglutide

Criteria

Inclusion Criteria:

• Women aged 40-75 with angina-like symptoms assessed by the Seattle Angina Questionnaire (SAQ).

• Women aged 40-75 with angina-like symptoms assessed by the Seattle Angina Questionnaire (SAQ).

• Referred for ischemic heart disease (IHD) assessment with no significant coronary stenosis (>50%) at coronary angiography or CT-angiography

• Impaired CFR assessed by echo Doppler flow (defined ratio≤2,5).

• BMI≥25kg/m2

Exclusion Criteria:

• Allergy to dipyridamole, theophyllamine or liraglutide

• Previous myocardial infarction or revascularization

• No episodes of chest pain within 6 months before inclusion

• Diabetes (reported, noted in journal or patient on antidiabetic medication)

• Other causes of chest discomfort deemed highly likely

• Left ventricular ejection fraction <45

• Significant valvular disease

• Congenital heart disease

• severe co-morbidity with limited life-expectancy< 1 year

• Severe asthma

• Severe chronic obstructive pulmonary disease

• Pregnancy (pregnancy test will be done at inclusion)

• No use of contraception although in child-bearing age. A woman is regarded fertile, following menarche and until becoming post-menopausal unless permanently sterile. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. The birth control methods considered safe and effective includes combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable), intrauterine device (IUD) and intrauterine hormone-releasing system ( IUS). Women in child-bearing age will have to use one of the above mentioned contraceptive methods from inclusion in the study until the end of study participation.

• physical or mental disability

• active cancer

• significant renal (eGRF<30) or hepatic co-morbidity

• chronic alcohol abuse

• atrial fibrillation

• Atrio-ventricular block>1st degree

• chronic or previous acute pancreatitis

• inflammatory bowel disease

• history of thyroid carcinoma

• participation in other clinical trial if relevant for the present study.

• Language- or other barrier to giving informed consent

• No signed informed consent